MOG (35-55), human

This human MOG (35-55) peptide, featuring a Pro42Ser substitution, is immunogenic and cross-reactive with its rodent counterpart but exhibits minimal encephalitogenicity and induces only mild EAE symptoms. It serves as a critical tool for comparative neuroimmunology research, specifically in studying T-cell responses and epitope specificity in models of autoimmune demyelination.